Add Your Heading Text Here

RPM Dashboard
Article

Evolution of the digital health spectrum of care

5 min read

A post written by Jessica Shull (Digital Therapeutics Alliance), Dr. Keith Grimes (Babylon Health), and Alexandra Yembele (Withings). Last edit: October, 8th

Health systems are evolving beyond the doctor’s office

Countries aim to improve current standards of care for their populations while developing novel ways to treat patients with acute health conditions. This evolution has only quickened in the midst of a continuously shifting pandemic, and the result of this adaptation is the adoption of digital health technologies (DHT) and the care spectrum evolution. Although DHT has been developing for the last 20 years, the physical dangers of being together during a pandemic has sped up the need for doctors to be able to collect actionable insights and extend care beyond the office setting. The advances in DHT could offer integrated care for whole populations in countries across the globe while providing tools so that potentially, no one is left behind.

New solutions for new challenges

There are several examples that show how healthcare systems are adopting innovative pathways for DHTs. Three examples include:

     

      • As part of insurance benefits in some countries, employers are utilizing connected devices like sleep trackers and heart rate monitors to encourage employees to improve health indicators;

      • In 2019, few physicians in Germany utilized telemedicine platforms (virtual visits with patients via phone or online), but this year there was a 200% increase in some parts of the country due to the pandemic.

    These examples highlight countries’ need to find new ways to interact with patients and provide care within existing healthcare systems.

    The best-case scenario is when these three resources — digital therapeutics, remote patient monitoring, and telemedicine platforms — work together. This trio of digital health technologies and the care spectrum evolution can be used to assist a wide variety of patients including those who have for example, hypertension, diabetes, implant receivers, and or COPD.

    The ideal DHT Combination

    The European Respiratory Society estimates 15–20% of adults over 40 in Europe suffer from this Chronic Obstructive Pulmonary Disease (COPD). A typical patient, who we’ll call Maria, might visit a doctor every six months for routine COPD checkups, but collecting data biannually may not provide the information needed to see important health trends and anticipate potential complications. Rather than relying on these infrequent visits, COPD patients could access the benefits of DHT via digital care products to manage the disease.

    Firstly, this type of patient needs access to personal medical devices that can actively monitor health at home or on the go. The Withings ScanWatch is an example of a connected device that can monitor this patient’s oxygen saturation and daily walking distance multiple times a day rather than the typical protocol, which is to wait six months to measure indicators in hospital. The next step towards DHT solutions entails the bridge between patients’ data and medical providers. Combined with the care spectrum evolution, the backend integration of Withings’ open API allows Babylon, a telemedicine platform, to automatically and safely receive data that patients have authorized to be sent. Medical providers would then have on-demand access to the data and can adjust this patient’s medications accordingly while also monitoring the long-term effectiveness of treatment.

    In addition to the medical device and telemedicine bridge between patient and provider, using a companion digital therapeutics (DTx) for COPD could help improve patient outcomes. The DTx is clinically-validated, works with medications, tracks triggers that reduce oxygen levels, and helps adjust key behaviors to optimize overall condition. Due to the insights provided via the DTx, COPD patients can avoid taking walks on days with high levels of air pollution, lower the use of rescue inhalers, understand how to best exercise, and experience reduced dyspnoea episodes.

    The combination of device, telemedicine, and DTx is a suite of technologies composing DHT that can help patients and providers co-create care plans that help identify goals and well-defined actions to improve health and change key behaviors. While patients can still check in every 6 months with providers, with the care spectrum evolution, data is being delivered more frequently which could reduce hospital visits and deliver better health indicators.

    However, dumping large amounts of patient vitals every day is not the answer, which is why providers can enable a series of alerts that initiate a clinician review based on patient triggers revolving around personal conditions and health history. In this case, doctors only see the information that is needed, not daily dumps of data.

    Who are the DHT minds behind this article?

    Babylon Health

    Babylon Health is a globally leading technology company with the ambitious mission to put an accessible and affordable health service in the hands of every person on Earth. We combine technology and medical expertise to bring doctors and people closer together, with digital health tools designed to empower people with knowledge about their health. Through a range of digital health services — such as an AI-backed app and video doctor appointments — we provide around-the-clock access to affordable, holistic healthcare services and information. We work with governments, health providers and insurers across the globe, and healthcare facilities from small local practices to large hospitals. With a $2Bn valuation, Babylon covers 20 million people across the globe, and has delivered more than 8m virtual consultations and AI interactions. We have teamed up with 170 impactful worldwide partners — including Mount Sinai Health Partners, the NHS, Telus Health, the Bill & Melinda Gates Foundation and the Government of Rwanda — to fulfil our vision of accessible and affordable healthcare, for all. For more information, visit https://www.babylonhealth.com

    Withings

    Withings produces medical grade devices for at-home monitoring so that patients can understand with precision their symptoms and trends in indicators. Withings’ mission is to continuously and effortlessly provide healthcare professionals with medical-grade data generated by patients from an ecosystem of connected devices. For more than a decade, Withings has built a range of award-winning products including activity trackers, connected scales, a wireless blood pressure monitor, a smart temporal thermometer, and an advanced sleep system. From remote patient monitoring to clinical research to chronic disease management, Withings has dedicated solutions that provide the richest array of accurate real-world data thanks to a complete ecosystem of connected devices, data connectivity options, and a remote patient monitoring platform. Visit our website here.

    Digital Therapeutics Alliance

    Founded in 2017, the Digital Therapeutics Alliance (DTA) is a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. DTA maintains an international industry focus and is headquartered in the United States. DTA exists to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics into healthcare through education, advocacy, and research. In Europe, digital therapeutics offer regulated, CE marked digital therapies to patients with a diagnosed condition or disease. Most DTx products in Europe require third-party authorization or a prescription from a qualified clinician. Digital therapeutics undergo clinical trials, collect real world outcomes, and are based on patient-centered core principles and product development best practices, including product design, usability, data security, and privacy standards.

    Don’t miss out,  subscribe to get the latest content updates.  

    Related Content

    WP_Query Object ( [query] => Array ( [post_type] => post [post_status] => publish [orderby] => date [order] => DESC [ignore_sticky_posts] => 1 [post__not_in] => Array ( [0] => 361 ) [cat] => 18 [posts_per_page] => 3 ) [query_vars] => Array ( [post_type] => post [post_status] => publish [orderby] => date [order] => DESC [ignore_sticky_posts] => 1 [post__not_in] => Array ( [0] => 361 ) [cat] => 18 [posts_per_page] => 3 [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => articles [tag] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [s] => [sentence] => [title] => [fields] => all [menu_order] => => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [search_columns] => Array ( ) [suppress_filters] => [cache_results] => 1 [update_post_term_cache] => 1 [update_menu_item_cache] => [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => [comments_per_page] => 50 [no_found_rows] => ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( [0] => Array ( [taxonomy] => category [terms] => Array ( [0] => 18 ) [field] => term_id [operator] => IN [include_children] => 1 ) ) [relation] => AND [table_aliases:protected] => Array ( [0] => wp_term_relationships ) [queried_terms] => Array ( [category] => Array ( [terms] => Array ( [0] => 18 ) [field] => term_id ) ) [primary_table] => wp_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) WHERE 1=1 AND wp_posts.ID NOT IN (361) AND ( wp_term_relationships.term_taxonomy_id IN (18) ) AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish')) GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC LIMIT 0, 3 [posts] => Array ( [0] => WP_Post Object ( [ID] => 2100 [post_author] => 11 [post_date] => 2026-01-06 15:23:33 [post_date_gmt] => 2026-01-06 15:23:33 [post_content] =>

    Introduction

    Wearable ECG technology is increasingly used to support ambulatory cardiac rhythm monitoring, but questions remain about how these tools fit into patients’ daily lives.

     

    A recent qualitative study conducted in the Netherlands explored this issue by comparing patient experiences using a smartwatch with single-lead ECG (1L-ECG) capability and a traditional Holter monitor over the course of one week.

     

    The findings offer useful insights into the practical benefits and limitations of smartwatch-based ECG monitoring and what matters most to patients when rhythm monitoring moves beyond the clinic.

    Study Overview

    The study included 18 adults referred for ambulatory rhythm monitoring at a diagnostic center in the Netherlands, specifically through referrals from primary care to the cardiology outpatient clinic of the Dijklander Hospital in Hoorn. Participants were aged 32–85, with a median age of 66.

     

    Each participant wore both:

    • A smartwatch with 1L-ECG capability (Withings ScanWatch), and
    • A conventional chest-worn Holter monitor

    for seven days. Afterward, researchers conducted semi-structured interviews to understand their experiences with usability, comfort, confidence, and perceived clinical value.

     

    Rather than focusing on diagnostic accuracy, the study centred on how patients experienced the monitoring process itself, an increasingly important consideration as wearable technologies become more common in routine care.

    What Patients Reported

     

    Comfort and Ease of Use

    Participants consistently described the smartwatch as easier to wear and less intrusive than the Holter monitor. Wearing the watch felt familiar and fit naturally into daily routines, including sleep and regular activities. In contrast, the Holter monitor’s electrodes and wiring were more noticeable and, for some, uncomfortable over time.

     

    Several participants noted skin irritation or inconvenience associated with adhesive electrodes, whereas the smartwatch was generally described as something they could wear without significant disruption to daily life.

     

    “It’s a bit heavier than my own smartwatch. That takes a minute to get used to, but after that you don’t even notice it anymore. It’s waterproof, so you barely notice you’re wearing it — not even at night, since I always sleep with a watch on. I don’t feel the difference anymore. Other than that, it does what it’s supposed to do: tell the time. Which is pretty handy, too.”
    P16, male patient, 48 years

     

    Capturing Symptoms in Real Life

    One of the key differences between the two approaches is how data are captured. The Holter monitor records continuously, while the smartwatch requires users to actively initiate an ECG recording.

     

    Participants appreciated having control over recordings but also expressed uncertainty about when to trigger them, particularly when symptoms were brief, unexpected, or occurred during sleep or activities like driving. This highlights a trade-off between passive continuous monitoring and more user-driven approaches.

     

    Automated ECG Results: Reassurance and Uncertainty

    Some participants found algorithm-based ECG feedback reassuring, especially when results were reported as normal. Others described moments of uncertainty or anxiety when the smartwatch flagged potential abnormalities without immediate clinical context.

     

    This finding underscores the importance of clear patient education and pathways for clinical follow-up when wearable ECG data are shared directly with users.

     

    Integration With Clinical Care

    Across interviews, participants emphasized that wearable ECG data felt most valuable when it could be reviewed by a healthcare professional. Many expressed a desire for smoother integration between smartwatch ECG recordings and clinical systems, as well as clearer guidance on how and when clinicians would review their data.

     

    Patients generally viewed the smartwatch as a helpful complement to traditional monitoring, particularly when combined with clinician oversight, rather than a complete replacement.

    Implications for Wearable ECG Monitoring

     

    Overall, the study suggests that smartwatch-based 1L-ECG monitoring is acceptable to patients and may reduce some of the burden associated with traditional Holter monitoring, particularly in terms of comfort and day-to-day wearability.

     

    At the same time, the findings point to areas where wearable ECG programs can improve:

    • Providing clearer guidance on when and how to record symptoms
    • Reducing uncertainty around automated ECG interpretations
    • Ensuring timely clinician review and communication

    As devices like the Withings ScanWatch continue to be used in real-world clinical settings, patient experience will remain a critical factor alongside clinical validation.

    Looking Forward

    This study adds to a growing body of evidence showing that wearable ECG devices can support ambulatory rhythm monitoring in ways that align more closely with everyday life. Designing these tools and the care pathways around them with patient experience in mind will be key to realizing their full potential in clinical practice.

     

    For more research-driven insights on connected health and remote monitoring, explore the latest updates on the Withings blog.

    Interested in partnering with us?

    Contact Us [post_title] => Patient Experiences With Smartwatch ECG Monitoring Compared to Traditional Holter Devices [post_excerpt] => A recent qualitative study conducted in the Netherlands compares patient experiences using a smartwatch with single-lead ECG (1L-ECG) capability and a traditional Holter monitor over the course of one week. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => patient-experiences-with-smartwatch-ecg-monitoring-compared-to-traditional-holter-devices [to_ping] => [pinged] => [post_modified] => 2026-01-06 15:51:03 [post_modified_gmt] => 2026-01-06 15:51:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://withingshealthsolutions.com/?p=2100 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2088 [post_author] => 11 [post_date] => 2025-12-15 15:48:18 [post_date_gmt] => 2025-12-15 15:48:18 [post_content] =>

    The World Health Organization recently released its first global guideline on the use of GLP-1–based therapies for obesity, a milestone that signals a major shift in how health systems worldwide should approach long-term obesity care.

     

    For obesity programs, digital-health organizations, and chronic-care providers, the message is clear: GLP-1s can be valuable tools, but only when embedded within a structured framework of behavioral support, lifestyle intervention, and ongoing monitoring.

    Here’s a guide to what programs need to understand and how to prepare.

     

    1. WHO Defines Obesity as a Chronic, Relapsing Disease, Not a Short-Term Problem or Fix

    The guideline reinforces a position many clinicians already share: obesity requires ongoing management similar to other chronic diseases. This means obesity programs must prioritize continuity, long-term engagement, and structured monitoring, not episodic care. Many times patients see weight loss as a goal that they reach and that concludes their obesity care journey. The WHO emphasizes the ongoing nature of obesity as a disease, and obesity care as a necessity.

     

    2. GLP-1s Are Recommended Conditionally and Only as Part of Comprehensive Care

    WHO does not recommend medication alone. The guideline emphasizes:
    GLP-1 therapies should be considered as one component of a broader care plan.

    Treatment decisions should reflect patient context, preferences, and access. Programs must integrate behavioral interventions and lifestyle support alongside medication. For organizations delivering obesity care, this signals a need to strengthen or formalize their behavioral-support models, including: coaching, education, medical nutrition therapy (MNT), activity support, and digital engagement.

     

    3. Behavioral Support Is Essential-Not Optional

    The guideline places intensive behavioral therapy (IBT) at the center of obesity care. Programs should ensure they can offer:

    • Structured lifestyle guidance
    • Goal setting and personalized plans
    • Coaching or counseling pathways
    • Tools for sustained behavior change
    • Ongoing check-ins and accountability
    • Medical nutrition therapy (MNT) when needed

    This isn’t merely additive, it is foundational to responsible GLP-1 prescribing and to long-term patient outcomes.

     

    4. Monitoring Frameworks Must Become Core Infrastructure

    One of the most operationally important implications for obesity programs is WHO’s emphasis on continuous monitoring and follow-up. Because obesity is chronic and GLP-1 outcomes evolve over time, programs need systems that can:

    • Track weight, body composition, and metabolic markers
    • Detect early signs of weight regain or treatment non-response
    • Support long-term engagement after dose changes or discontinuation
    • Ensure care teams can intervene proactively and remain the decision makers

    This is where digital health infrastructure becomes essential. Connected devices, remote monitoring, and automated data flows make it possible to support thousands of patients consistently without adding extensive labor burden to clinical teams.

     

    5. What Obesity Programs Should Do Next

    To align with WHO’s guidance and strengthen patient outcomes, programs can begin by:

    • Evaluating their behavioral-support offering - ensuring it is structured, consistent, and accessible.
    • Implementing device-based monitoring- enabling ongoing, objective tracking of patient progress without the barriers of in-office care.
    • Ensuring continuity models beyond initial weight loss - including maintenance and relapse-prevention.
    • Building customizable data workflows that let care teams intervene early, efficiently, and at scale, while keeping the decision-making in the hands of the clinician.
    • Partnering with technology providers already equipped to deliver these components reliably.

    The Bottom Line for Obesity Programs

    The new WHO guideline is not simply a statement on medications. It is a blueprint for comprehensive, long-term obesity care. Programs that combine medication, behavioral support, and robust monitoring will be best positioned to deliver durable outcomes, meet patient expectations, reduce clinical burden, and scale responsibly.


    Withings Health Solutions stands ready to support that evolution with the technology, partnerships, and evidence-aligned frameworks that make multimodal obesity care possible.

    Interested in partnering with us?

    Contact Us [post_title] => What Obesity Care Programs Need to Know About WHO’s New GLP-1 Guidelines [post_excerpt] => Learn what obesity care programs need to know about the new World Health Organization GLP-1 guidelines for obesity care. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => what-obesity-care-programs-need-to-know-about-whos-new-obesity-treatment-guidelines [to_ping] => [pinged] => [post_modified] => 2026-01-06 14:26:20 [post_modified_gmt] => 2026-01-06 14:26:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://withingshealthsolutions.com/?p=2088 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2083 [post_author] => 11 [post_date] => 2025-12-02 20:22:02 [post_date_gmt] => 2025-12-02 20:22:02 [post_content] =>

    Chronic Kidney Disease stage 5 on dialysis (CKD5D) presents one of the most complex and high-risk scenarios in modern medicine. Among the many challenges faced by these patients, cardiovascular disease (CVD) stands out as the leading cause of mortality—a stark reminder of the systemic stress that accompanies kidney failure and dialysis.

     

    But what if technology could help bridge the gap between dialysis sessions, offering clinicians a window into the patient's health in real-time? An article in Frontiers in Nephrology explores exactly that, highlighting the transformative potential of digital health technologies to monitor and manage CKD5D patients beyond the clinic.

    The Hidden Risks Between Dialysis Sessions

    For CKD5D patients, the risks of CVD are amplified by both traditional and disease-specific factors:

    • Traditional risks like hypertension, diabetes, and obesity.
    • CKD-specific risks such as inflammation, fluid overload, protein-energy wasting and vascular calcification.
    • The dialysis process itself, which induces rapid fluid shifts, blood pressure fluctuations, and metabolic imbalances.

    Current clinical care models often focus on in-center dialysis data, leaving a crucial blind spot during the interdialytic period—a time when many adverse events begin to develop unnoticed.

    A New Monitoring Paradigm: The Withings Toolkit

    The article introduces a compelling case for home-based, connected health technologies—specifically, the Withings toolkit. This suite of medical-grade, consumer-friendly devices allows CKD patients to monitor key health indicators in the comfort of their homes:

    • Weight, body composition and ECG monitoring with the BodyScan smart scale.
    • Blood pressure, heart rate and survey responses for added context via BPM Pro 2.
    • Sleep quality and breathing event metrics using the Sleep Rx.

    All data is seamlessly uploaded to the Withings Remote Patient Monitoring platform, providing healthcare providers and researchers with real-time, longitudinal insights into a patient’s well-being.

    Why This Matters: Real-World Clinical Benefits

     

    1. Early Detection of Complications
    Weight gain could signal fluid retention, but muscle loss could indicate protein-energy wasting. A sudden spike in blood pressure or irregular heartbeat might indicate arrhythmias or volume overload. Poor sleep patterns could reflect apnea or restless leg syndrome—conditions with known ties to CKD.

     

    2. Personalized, Data-Driven Care
    These devices enable a dynamic view of health trends, allowing clinicians to tailor treatments proactively rather than reactively. Medication adjustments, fluid restrictions, or further diagnostics can be made with greater confidence.

     

    3. Patient Empowerment

    When patients can see and understand their own data, they become more engaged in their care. This promotes better self-management, increased treatment adherence, and a stronger sense of control over their condition.

     

    4. Systemic Healthcare Advantages
    Remote monitoring can reduce emergency visits and hospitalizations, easing the burden on overtaxed healthcare systems and offering a cost-effective alternative to frequent in-person evaluations.

    The Future: Digital Tools as Standard of Care?

    While still in its early stages, this integration of digital health into CKD care reflects a broader movement toward remote, preventative, and personalized medicine. The Withings case study serves as a promising example of how everyday technology can be adapted to serve complex clinical needs.

     

    However, as the authors note, more clinical trials are needed to validate these tools in nephrology settings, establish protocols for data use, and ensure equitable access across diverse patient populations.

    Final Thoughts

    As we face growing rates of kidney disease and limited nephrology resources, connected health technologies offer a lifeline—not just to patients, but to an entire care infrastructure in need of modernization.


    The Withings toolkit is more than a gadget suite; it's a glimpse into the future of chronic disease management, where data flows continuously, care is adaptive, and patients are active participants in their own health journey.

    Reference:
    Article: Frontiers in Nephrology, 2023 - DOI: 10.3389/fneph.2023.1148565

    Interested in partnering with us?

    Contact Us [post_title] => Revolutionizing Chronic Kidney Disease Management with Digital Health Tools: The Withings Case Study [post_excerpt] => Researchers from Imperial College London explored how continuous, contactless sleep monitoring using the Withings Sleep Analyzer can be used to detect acute conditions, focusing particularly on urinary tract infections (UTIs) before patients even recognize symptoms. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => revolutionizing-chronic-kidney-disease-management-with-digital-health-tools-the-withings-case-study [to_ping] => [pinged] => [post_modified] => 2025-12-02 20:22:24 [post_modified_gmt] => 2025-12-02 20:22:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://withingshealthsolutions.com/?p=2083 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 3 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 2100 [post_author] => 11 [post_date] => 2026-01-06 15:23:33 [post_date_gmt] => 2026-01-06 15:23:33 [post_content] =>

    Introduction

    Wearable ECG technology is increasingly used to support ambulatory cardiac rhythm monitoring, but questions remain about how these tools fit into patients’ daily lives.

     

    A recent qualitative study conducted in the Netherlands explored this issue by comparing patient experiences using a smartwatch with single-lead ECG (1L-ECG) capability and a traditional Holter monitor over the course of one week.

     

    The findings offer useful insights into the practical benefits and limitations of smartwatch-based ECG monitoring and what matters most to patients when rhythm monitoring moves beyond the clinic.

    Study Overview

    The study included 18 adults referred for ambulatory rhythm monitoring at a diagnostic center in the Netherlands, specifically through referrals from primary care to the cardiology outpatient clinic of the Dijklander Hospital in Hoorn. Participants were aged 32–85, with a median age of 66.

     

    Each participant wore both:

    • A smartwatch with 1L-ECG capability (Withings ScanWatch), and
    • A conventional chest-worn Holter monitor

    for seven days. Afterward, researchers conducted semi-structured interviews to understand their experiences with usability, comfort, confidence, and perceived clinical value.

     

    Rather than focusing on diagnostic accuracy, the study centred on how patients experienced the monitoring process itself, an increasingly important consideration as wearable technologies become more common in routine care.

    What Patients Reported

     

    Comfort and Ease of Use

    Participants consistently described the smartwatch as easier to wear and less intrusive than the Holter monitor. Wearing the watch felt familiar and fit naturally into daily routines, including sleep and regular activities. In contrast, the Holter monitor’s electrodes and wiring were more noticeable and, for some, uncomfortable over time.

     

    Several participants noted skin irritation or inconvenience associated with adhesive electrodes, whereas the smartwatch was generally described as something they could wear without significant disruption to daily life.

     

    “It’s a bit heavier than my own smartwatch. That takes a minute to get used to, but after that you don’t even notice it anymore. It’s waterproof, so you barely notice you’re wearing it — not even at night, since I always sleep with a watch on. I don’t feel the difference anymore. Other than that, it does what it’s supposed to do: tell the time. Which is pretty handy, too.”
    P16, male patient, 48 years

     

    Capturing Symptoms in Real Life

    One of the key differences between the two approaches is how data are captured. The Holter monitor records continuously, while the smartwatch requires users to actively initiate an ECG recording.

     

    Participants appreciated having control over recordings but also expressed uncertainty about when to trigger them, particularly when symptoms were brief, unexpected, or occurred during sleep or activities like driving. This highlights a trade-off between passive continuous monitoring and more user-driven approaches.

     

    Automated ECG Results: Reassurance and Uncertainty

    Some participants found algorithm-based ECG feedback reassuring, especially when results were reported as normal. Others described moments of uncertainty or anxiety when the smartwatch flagged potential abnormalities without immediate clinical context.

     

    This finding underscores the importance of clear patient education and pathways for clinical follow-up when wearable ECG data are shared directly with users.

     

    Integration With Clinical Care

    Across interviews, participants emphasized that wearable ECG data felt most valuable when it could be reviewed by a healthcare professional. Many expressed a desire for smoother integration between smartwatch ECG recordings and clinical systems, as well as clearer guidance on how and when clinicians would review their data.

     

    Patients generally viewed the smartwatch as a helpful complement to traditional monitoring, particularly when combined with clinician oversight, rather than a complete replacement.

    Implications for Wearable ECG Monitoring

     

    Overall, the study suggests that smartwatch-based 1L-ECG monitoring is acceptable to patients and may reduce some of the burden associated with traditional Holter monitoring, particularly in terms of comfort and day-to-day wearability.

     

    At the same time, the findings point to areas where wearable ECG programs can improve:

    • Providing clearer guidance on when and how to record symptoms
    • Reducing uncertainty around automated ECG interpretations
    • Ensuring timely clinician review and communication

    As devices like the Withings ScanWatch continue to be used in real-world clinical settings, patient experience will remain a critical factor alongside clinical validation.

    Looking Forward

    This study adds to a growing body of evidence showing that wearable ECG devices can support ambulatory rhythm monitoring in ways that align more closely with everyday life. Designing these tools and the care pathways around them with patient experience in mind will be key to realizing their full potential in clinical practice.

     

    For more research-driven insights on connected health and remote monitoring, explore the latest updates on the Withings blog.

    Interested in partnering with us?

    Contact Us [post_title] => Patient Experiences With Smartwatch ECG Monitoring Compared to Traditional Holter Devices [post_excerpt] => A recent qualitative study conducted in the Netherlands compares patient experiences using a smartwatch with single-lead ECG (1L-ECG) capability and a traditional Holter monitor over the course of one week. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => patient-experiences-with-smartwatch-ecg-monitoring-compared-to-traditional-holter-devices [to_ping] => [pinged] => [post_modified] => 2026-01-06 15:51:03 [post_modified_gmt] => 2026-01-06 15:51:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://withingshealthsolutions.com/?p=2100 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 54 [max_num_pages] => 18 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => 1 [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => 1 [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 614d63474ceb6a92992fe407c9b61a95 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => wp_query:acdf33e1034226757142574397276424 )
    Article

    Patient Experiences With Smartwatch ECG Monitoring Compared to Traditional Holter Devices

    Read More
    Article

    What Obesity Care Programs Need to Know About WHO’s New GLP-1 Guidelines

    Read More
    Article

    Revolutionizing Chronic Kidney Disease Management with Digital Health Tools: The Withings Case Study

    Read More

    Withings On-The-Go

    Our patient-centric care solution utilizes portable Withings cellular devices that are not tied to a single patient. Instead, care teams can use one device to collect and transmit data for an unlimited number of individuals. The integrated cellular connectivity automatically directs the data into the correct patient’s medical record, simplifying data collection and improving care delivery regardless of the setting.
    Interested? Contact Us